{"content":"<li class=\"n-box-item date-title\" data-end=\"1502942399\" data-start=\"1502856000\" data-txt=\"Monday, December 23, 2019\">Wednesday, August 16, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3290022\" data-ts=\"1502927880\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LGF.A\" target=\"_blank\">LGF.A</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290022-lions-gate-announces-first-branded-theme-park-for-south-korea\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lions Gate announces first branded theme park, for South Korea</a></h4><ul>   <li>Lions Gate (<a href='https://seekingalpha.com/symbol/LGF.A' title='Lions Gate Entertainment Corp.'>LGF.A</a> <font color='green'>+5.1%</font>, <a href='https://seekingalpha.com/symbol/LGF.B' title='Lions Gate Entertainment Corp.'>LGF.B</a> <font color='green'>+2.8%</font>) and development company Landing Jeju have announced plans for <a href=\"http://www.traveldailynews.asia/news/article/65831/lionsgate-and-landing-jeju-announce\" target=\"_blank\">Lionsgate Movie World</a> in South Korea, the studio's first branded outdoor theme park.</li>    <li>The attraction will be located at Jeju Shinhwa World, where it will be the centerpiece, and cover 1.3M square feet.</li>    <li>It will be focused on seven movie zones themed around studio properties, including <i>The Hunger Games, Twilight, Now You See Me</i> and 2018 release <i>Robin Hood.</i></li>    <li>The park will begin construction in 2018 for a 2019 opening.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3290022\" data-linked=\"Lions Gate announces first branded theme park, for South Korea\" data-tweet=\"$LGF.A $LGF.A $LGF.B - Lions Gate announces first branded theme park, for South Korea https://seekingalpha.com/news/3290022-lions-gate-announces-first-branded-theme-park-for-south-korea?source=tweet\" data-url=\"https://seekingalpha.com/news/3290022-lions-gate-announces-first-branded-theme-park-for-south-korea\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290019\" data-ts=\"1502925821\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSCO\" target=\"_blank\">CSCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290019-cisco-realigning-revenue-categories-model-evolves\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cisco realigning revenue categories as model evolves</a></h4><ul>   <li>On its earnings conference call, Cisco Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CSCO' title='Cisco Systems, Inc.'>CSCO</a>) said it was changing up its <a href=\"http://www.barrons.com/articles/cisco-to-change-reporting-into-five-categories-to-better-align-with-evolving-biz-model-1502918224\" target=\"_blank\">revenue reporting categories</a> in order to \"better align with our evolving business model.\"</li>    <li>The company saw revenues in its key Switching and NGN Routing categories <a href=\"https://seekingalpha.com/news/3289969-cisco-minus-1_2-percent-q4-earnings-beat-shows-declining-sales-profits\" target=\"_blank\">each decline by 9%</a> for the quarter, while Wireless revenues rose 5% and Security rose 3%.</li>    <li>Now the firm will sort revenue differently: Infrastructure Platform, Applications, Security, Services, and other.</li>    <li>Book-to-bill ratio was \"comfortably above 1\" at quarter's end, the company added.</li>    <li>Cisco shares are now <font color='red'>down 2.6%</font> in after-hours trade.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3290019\" data-linked=\"Cisco realigning revenue categories as model evolves\" data-tweet=\"$CSCO - Cisco realigning revenue categories as model evolves https://seekingalpha.com/news/3290019-cisco-realigning-revenue-categories-model-evolves?source=tweet\" data-url=\"https://seekingalpha.com/news/3290019-cisco-realigning-revenue-categories-model-evolves\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290006\" data-ts=\"1502920028\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HHS\" target=\"_blank\">HHS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290006-harte-hanks-points-to-revenue-improvements-q1-sales-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Harte Hanks points to revenue improvements with Q1 sales beat</a></h4><ul>   <li>Harte Hanks (<a href=\"http://seekingalpha.com/symbol/HHS\" target=\"_blank\">HHS</a> <font color='green'>+4.2%</font>) is <font color='green'>up 12.1%</font> in a few postmarket trades after posting its <a href=\"https://seekingalpha.com/news/3289974-harte-hanks-misses-0_05-beats-revenue\" target=\"_blank\">Q1 earnings</a> that continued to show slowing declines in revenues.</li>    <li>Operating loss improved by $2.2M to $6.3M vs. a year-ago $8.5M.</li>    <li>Net loss came to $7.4M, vs. a year-ago loss of $5.6M.</li>    <li>We used approximately $2.4 million in cash in the first quarter,\" says CFO Robert Munden. \"We anticipate lower customer turnover from increased customer satisfaction. We are also benefiting from an increase in new client bookings and continued cost controls. We expect cash flows will improve in the second half of the year.</li>    <li>Revenue shares by vertical markets: B2B, 22.8%; Consumer, 22.2%; Financial Services, 16%; Healthcare, 6.2%; Retail, 24.3%; Transportation, 8.5%.</li>    <li><a href=\"https://seekingalpha.com/pr/16917751-harte-hanks-reports-first-quarter-2017-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3290006\" data-linked=\"Harte Hanks points to revenue improvements with Q1 sales beat\" data-tweet=\"$HHS - Harte Hanks points to revenue improvements with Q1 sales beat https://seekingalpha.com/news/3290006-harte-hanks-points-to-revenue-improvements-q1-sales-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3290006-harte-hanks-points-to-revenue-improvements-q1-sales-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290004\" data-ts=\"1502919392\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290004-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/REN' title='Resolute Energy Corporation'>REN</a> <font color='green'>+10.0%</font>. <a href='https://seekingalpha.com/symbol/AERI' title='Aerie Pharmaceuticals, Inc.'>AERI</a> <font color='green'>+3.8%</font>. <a href='https://seekingalpha.com/symbol/HFC' title='HollyFrontier Corp.'>HFC</a> <font color='green'>+2.7%</font>. <a href='https://seekingalpha.com/symbol/CARB' title='Carbonite Inc.'>CARB</a> <font color='green'>+2.7%</font>. <a href='https://seekingalpha.com/symbol/BBOX' title='Black Box Corporation'>BBOX</a> <font color='green'>+2.7%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/LAKE' title='Lakeland Industries, Inc.'>LAKE</a> <font color='red'>-10.5%</font>. <a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a> <font color='red'>-6.3%</font>. <a href='https://seekingalpha.com/symbol/VIPS' title='Vipshop Holdings'>VIPS</a> <font color='red'>-6.3%</font>. <a href='https://seekingalpha.com/symbol/FNGN' title='Financial Engines, Inc.'>FNGN</a> <font color='red'>-3.9%</font>. <a href='https://seekingalpha.com/symbol/ACHC' title='Acadia Healthcare Co.'>ACHC</a> <font color='red'>-2.3%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3290004\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$REN $AERI $HFC - After Hours Gainers / Losers https://seekingalpha.com/news/3290004-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3290004-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289997\" data-ts=\"1502917372\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LB\" target=\"_blank\">LB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289997-l-brands-slumps-after-soft-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">L Brands slumps after soft guidance</a></h4><ul>     <li>L Brands (NYSE:<a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a>) falls after setting guidance below expectations.The company already preannounced the Q2 results, leaving the guidance the headline event of today's report.</li>     <li>The retailer sees Q3 EPS of $0.25 to $0.30 vs. $0.36 consensus. and FY18 EPS of $3.00 to $3.20 vs. $3.22 consensus.</li>     <li>Sales at L Brand continue to fall off after the decision to exit swim and apparel categories.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3289979-l-brands-beats-0_04-beats-revenue\" target=\"_blank\">L Brands beats by $0.04, beats on revenue</a> (Aug. 16)</li>     <li>Shares of LB are&nbsp;<font color='red'>down 7.21%</font>&nbsp;AH to $36.61 (multi-year low).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289997\" data-linked=\"L Brands slumps after soft guidance\" data-tweet=\"$LB - L Brands slumps after soft guidance https://seekingalpha.com/news/3289997-l-brands-slumps-after-soft-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3289997-l-brands-slumps-after-soft-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289991\" data-ts=\"1502917043\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACHC\" target=\"_blank\">ACHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289991-acadia-launches-2_8m-share-offering-existing-shareholders-shares-slip-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acadia launches 2.8M-share offering by existing shareholders; shares slip 3% after hours</a></h4><ul><li>Acadia Healthcare (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHC' title='Acadia Healthcare Co.'>ACHC</a>) is down&nbsp;<font color='red'>3%</font>&nbsp;after hours on modest volume on the heels of its <a href=\"https://seekingalpha.com/pr/16917778-acadia-healthcare-company-inc-announces-secondary-offering-2825-016-shares-common-stock\" target=\"_blank\">planned offering</a> of 2,825,016 shares of common stock from existing shareholders, including certain executives and directors of the company. Acadia will receive no proceeds from the offering.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289991\" data-linked=\"Acadia launches 2.8M-share offering by existing shareholders; shares slip 3% after hours\" data-tweet=\"$ACHC - Acadia launches 2.8M-share offering by existing shareholders; shares slip 3% after hours https://seekingalpha.com/news/3289991-acadia-launches-2_8m-share-offering-existing-shareholders-shares-slip-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3289991-acadia-launches-2_8m-share-offering-existing-shareholders-shares-slip-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289988\" data-ts=\"1502916050\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289988-fda-ok-valeants-b-l-site-in-florida-overhang-removed-from-regulatory-submissions-shares-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OK with Valeant&#39;s B + L site in Florida, overhang removed from regulatory submissions; shares ahead 1% after hours</a></h4><ul><li>Valeant Pharmaceuticals (VRX) <a href=\"https://seekingalpha.com/pr/16917737-valeant-receives-fda-confirmation-voluntary-action-indicated-vai-inspection-classification\" target=\"_blank\">announces </a>that the FDA has confirmed that it will issue a Voluntary Action Indicated &#40;VAI&#41; inspection classification for its Bausch + Lomb manufacturing facility in Tampa, FL. The VAI tag means that objectionable concerns were observed by FDA inspectors at the site, but the problems were below the threshold of regulatory significance.</li><li>The company's current and planned regulatory filings for products made in Tampa are now unencumbered by Current Good Manufacturing Practice &#40;CGMP&#41; issues. Valeant received a CRL last week related to its marketing application for IOP med latanoprostene bunod ophthalmic solution citing CGMP deficiencies at the facility.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;after hours on robust volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3286705-fda-rejects-valeants-marketing-application-iop-eye-drop-latanoprostene-bunod\" target=\"_blank\">FDA rejects Valeant's marketing application for IOP eye drop latanoprostene bunod</a> (Aug. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289988\" data-linked=\"FDA OK with Valeant&#39;s B + L site in Florida, overhang removed from regulatory submissions; shares ahead 1% after hours\" data-tweet=\"$BHC - FDA OK with Valeant&#39;s B + L site in Florida, overhang removed from regulatory submissions; shares ahead 1% after hours https://seekingalpha.com/news/3289988-fda-ok-valeants-b-l-site-in-florida-overhang-removed-from-regulatory-submissions-shares-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3289988-fda-ok-valeants-b-l-site-in-florida-overhang-removed-from-regulatory-submissions-shares-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>121&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289985\" data-ts=\"1502915769\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTAP\" target=\"_blank\">NTAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289985-netapp-beats-q1-estimates-shares-down-aftermarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NetApp beats Q1 estimates, shares down aftermarket</a></h4><ul><li>        NetApp (NASDAQ:<a href='https://seekingalpha.com/symbol/NTAP' title='NetApp, Inc.'>NTAP</a>) reports Q1 results with revenue and EPS beats. Product revenues were up 10% on the year to $723M. Software maintenance revenues were down 3%. Hardware maintenance and other services revenues were down 6% to $368M.</li><li>                  Non-GAAP gross margins by segment: Product, 49.9%; Software Maintenance, 97%; Hardware Maintenance and Other, 70.1%.    </li><li>               NetApp ended the quarter with $5.3B in cash and equivalents. The company generated $250M in cash from operations while returning $204M to shareholders.&nbsp;</li><li>               The next cash dividend of $0.20 per share will pay out on October 25 to shareholders of record at the close of business on October 6.</li><li>               Q2 outlook: revenue, $1.31B to $1.46B (consensus: $1.37B); EPS, $0.64 to $0.72 (consensus:$0.70).&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16917707-netapp-reports-first-quarter-fiscal-year-2018-results\" target=\"_blank\">Press release</a>&nbsp;</li><li>                  NetApp shares are&nbsp;<font color='red'>down 1.65%</font>&nbsp;aftermarket. </li><li>Previously: <a href=\"https://seekingalpha.com/news/3289956-netapp-beats-0_07-beats-revenue\" target=\"_blank\">NetApp beats by $0.07, beats on revenue</a> (Aug. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289985\" data-linked=\"NetApp beats Q1 estimates, shares down aftermarket\" data-tweet=\"$NTAP - NetApp beats Q1 estimates, shares down aftermarket https://seekingalpha.com/news/3289985-netapp-beats-q1-estimates-shares-down-aftermarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3289985-netapp-beats-q1-estimates-shares-down-aftermarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289982\" data-ts=\"1502915552\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIPS\" target=\"_blank\">VIPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289982-vipshopminus-5_8-q2-misses-on-profits-revenues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vipshop -5.8% as Q2 misses on profits, revenues</a></h4><ul>   <li>Vipshop Holdings (NYSE:<a href='https://seekingalpha.com/symbol/VIPS' title='Vipshop Holdings'>VIPS</a>) has <font color='red'>slipped 5.8%</font> in postmarket trades following the release of <a href=\"https://seekingalpha.com/news/3289962-vipshop-holdings-misses-0_02-misses-revenue\" target=\"_blank\">Q2 earnings</a> where revenues rose 30% but the company missed expectations on top and bottom lines.</li>    <li>Gross profit was up 19.1% to 3.86B yuan (about $569.4M), and non-GAAP net income rose 7.5%, to 728.2M yuan ($107.4M).</li>    <li>Active customers rose 22% to 28.1M; total orders rose 23%, to 84.8M. Average revenue per active customer was up 6.7% Y/Y driven by a 5.9% boost in average ticket size.</li>    <li>It had cash, equivalents and restricted cash at quarter's end of 4.2B yuan ($619.2M). Free cash flow was -$24.2M.</li>    <li>For Q3, it's guiding to net revenues of 14.9B-15.4B yuan (vs. consensus for 15.187B yuan, about $2.27B) representing growth in renminbi terms of 24-28%.</li>    <li><a href=\"http://ir.vip.com/\" target=\"_blank\">Conference call</a> to come tomorrow at 8 a.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16917721-vipshop-reports-unaudited-second-quarter-2017-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3289982\" data-linked=\"Vipshop -5.8% as Q2 misses on profits, revenues\" data-tweet=\"$VIPS - Vipshop -5.8% as Q2 misses on profits, revenues https://seekingalpha.com/news/3289982-vipshopminus-5_8-q2-misses-on-profits-revenues?source=tweet\" data-url=\"https://seekingalpha.com/news/3289982-vipshopminus-5_8-q2-misses-on-profits-revenues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289977\" data-ts=\"1502915153\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LAKE\" target=\"_blank\">LAKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289977-lakeland-preliminary-fiscal-q2-revenues-up-8-eps-high-0_21-shares-down-6-after-hours-on\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lakeland preliminary fiscal Q2 revenues up ~8%; EPS as high as $0.21; shares down 6% after hours on planned equity offering</a></h4><ul><li>Lakeland Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/LAKE' title='Lakeland Industries, Inc.'>LAKE</a>) preliminary&nbsp;<a href=\"https://seekingalpha.com/pr/16917704-lakeland-industries-announces-preliminary-financial-results-fiscal-2018-second-quarter-launch\" target=\"_blank\">fiscal Q2 results</a> ($M): Revenues: 23 - 25; Net Income: 1.4 - 1.6; EPS: 0.19 - 0.21.</li><li>Public offering of common stock being prepared. Net proceeds will fund manufacturing buildout overseas, capex, repayment of borrowings under line of credit and general corporate purposes.</li><li>Shares are down&nbsp;<font color='red'>6%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289977\" data-linked=\"Lakeland preliminary fiscal Q2 revenues up ~8%; EPS as high as $0.21; shares down 6% after hours on planned equity offering\" data-tweet=\"$LAKE - Lakeland preliminary fiscal Q2 revenues up ~8%; EPS as high as $0.21; shares down 6% after hours on planned equity offering https://seekingalpha.com/news/3289977-lakeland-preliminary-fiscal-q2-revenues-up-8-eps-high-0_21-shares-down-6-after-hours-on?source=tweet\" data-url=\"https://seekingalpha.com/news/3289977-lakeland-preliminary-fiscal-q2-revenues-up-8-eps-high-0_21-shares-down-6-after-hours-on\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289975\" data-ts=\"1502915102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289975-comp-sales-fall-5-stein-mart-shares-down-20\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Comp sales fall 5% at Stein Mart; shares down 20%</a></h4><ul><li>Comparable sales fell 5% from last year's Q2; total sales slid 2.7%.</li><li>Average store inventories are down 15% from a year ago.</li><li>Shares are&nbsp;<font color='red'>down 20%</font>&nbsp;in after hours action.</li><li><a href=\"http://files.shareholder.com/downloads/SMRT/5006758142x0x954120/80B0F9F2-8E33-43E0-93ED-575B07468924/Q2-17_IR_Presentation.pdf\" target=\"_blank\">Q2 presentation slides</a></li><li><a href=\"http://ir.steinmart.com\" target=\"_blank\">Conference call </a>at 4:30 ET</li><li>Previously: <a href=\"https://seekingalpha.com/news/3289965-stein-mart-eps-0_28\" target=\"_blank\">Stein Mart EPS of -$0.28</a> (Aug. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289975\" data-linked=\"Comp sales fall 5% at Stein Mart; shares down 20%\" data-tweet=\"Comp sales fall 5% at Stein Mart; shares down 20% https://seekingalpha.com/news/3289975-comp-sales-fall-5-stein-mart-shares-down-20?source=tweet\" data-url=\"https://seekingalpha.com/news/3289975-comp-sales-fall-5-stein-mart-shares-down-20\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289973\" data-ts=\"1502914702\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XCO\" target=\"_blank\">XCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289973-exco-resources-gets-nyse-non-compliance-letter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EXCO Resources gets NYSE non-compliance letter</a></h4><ul>     <li>EXCO Resources (NYSE:<a href='https://seekingalpha.com/symbol/XCO' title='EXCO Resources, Inc.'>XCO</a>) <font color='red'>-2.9%</font>&nbsp;AH after saying it received a <a href=\"https://seekingalpha.com/pr/16917688-exco-resources-inc-receives-notice-non-compliance-nyse-continued-listing-standards\" target=\"_blank\">notice of non-compliance</a> from the NYSE concerning the Exchange's continued listing standard for market cap, which fell below $50M over a trailing consecutive 30-day trading period.</li>     <li>XCO says it plans to notify the NYSE within 10 business days of its intent to cure the deficiency and return to compliance.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289973\" data-linked=\"EXCO Resources gets NYSE non-compliance letter\" data-tweet=\"$XCO - EXCO Resources gets NYSE non-compliance letter https://seekingalpha.com/news/3289973-exco-resources-gets-nyse-non-compliance-letter?source=tweet\" data-url=\"https://seekingalpha.com/news/3289973-exco-resources-gets-nyse-non-compliance-letter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289956\" data-ts=\"1502913808\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTAP\" target=\"_blank\">NTAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289956-netapp-beats-0_07-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NetApp beats by $0.07, beats on revenue</a></h4><ul><li>NetApp (NASDAQ:<a href='https://seekingalpha.com/symbol/NTAP' title='NetApp, Inc.'>NTAP</a>): Q1 EPS of $0.62 <font color='green'>beats by $0.07</font>.</li><li>Revenue of $1.33B (+3.1% Y/Y) <font color='green'>beats by $10M</font>.</li><li>Shares <font color='green'>+1.39%</font>.</li><li><a href='https://seekingalpha.com/pr/16917707-netapp-reports-first-quarter-fiscal-year-2018-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3289956\" data-linked=\"NetApp beats by $0.07, beats on revenue\" data-tweet=\"$NTAP - NetApp beats by $0.07, beats on revenue https://seekingalpha.com/news/3289956-netapp-beats-0_07-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3289956-netapp-beats-0_07-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289958\" data-ts=\"1502913530\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DORM\" target=\"_blank\">DORM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289958-dorman-productsminus-5-spruce-point-calls-strong-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dorman Products -5% as Spruce Point calls a Strong Sell</a></h4><ul>     <li>Dorman Products (<a href='https://seekingalpha.com/symbol/DORM' title='Dorman Products, Inc.'>DORM</a> <font color='red'>-4.8%</font>) sheds 5% after Spruce Point Capital issued a new research report that tagged the stock with a <a href=\"http://thefly.com/landingPageNews.php?id=2597364&amp;headline=DORM-Spruce-Point-puts-Strong-Sell-on-Dorman-sees--downside\" target=\"_blank\">Strong Sell rating</a>, predicting a 30%-50% downside, as it believes the stock's premium valuation is unwarranted.</li>     <li>Spruce Point says DORM's partnership with Amazon has driven the stock's outperformance but its channel checks indicate a potential risk that DORM could agitate its biggest customers; consensus expectations for DORM to continue growing top-line sales by 7% are unlikely in light of slowing growth of customers AutoZone, O'Reilly Auto and Advance Auto Parts.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289958\" data-linked=\"Dorman Products -5% as Spruce Point calls a Strong Sell\" data-tweet=\"$DORM - Dorman Products -5% as Spruce Point calls a Strong Sell https://seekingalpha.com/news/3289958-dorman-productsminus-5-spruce-point-calls-strong-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3289958-dorman-productsminus-5-spruce-point-calls-strong-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289951\" data-ts=\"1502912938\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIG\" target=\"_blank\">RIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289951-transocean-extends-losses-after-songa-deal-price-paid-for-rigs-staggering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Transocean extends losses after Songa deal; price paid for rigs &quot;staggering&quot;</a></h4><ul>     <li>Transocean (<a href='https://seekingalpha.com/symbol/RIG' title='Transocean Ltd.'>RIG</a> <font color='red'>-4.1%</font>) tumbles to a second straight day of new all-time lows following <a href=\"https://seekingalpha.com/news/3289355-transocean-acquire-songa-offshore\" target=\"_blank\">yesterday's $3.4B purchase</a> of rival Norwegian driller Songa Offshore.</li>     <li>Tudor Pickering Holt calls the deal an \"excellent strategic fit\" that will add to RIG's EBITDA, operating cash flow and net debt/EBITDA given Songa's strong fleet quality, which includes four new, purpose-built floaters working under long-term contracts with Statoil and a $4.1B backlog.</li>     <li>Credit Suisse analysts call it a \"<a href=\"http://www.barrons.com/articles/transocean-the-market-still-doesnt-like-the-deal-1502907893\" target=\"_blank\">good deal, not great</a>,\" citing Songa's \"good assets and backlog,\" $2.2B in debt with $1.8B of the amount tied to four 6G rigs; the firm says the price paid is \"a bit high but given the backlog and debt to EBTIDA at ~4x it was not going to be sold on the cheap.\"</li>     <li>Seaport Global Securities, however, thinks the deal is a <a href=\"https://www.forbes.com/sites/clairepoole/2017/08/15/analysts-differ-on-transoceans-pricey-acquisition-of-songa/\" target=\"_blank\">negative for RIG</a>, saying that while it enhances RIG's&nbsp;already strong position in the harsh environment floater market in Norway, the implied deal value of $850M per working rig and $485M per total rig is \"staggering,\" even for new generation rigs with a strong backlog position.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289951\" data-linked=\"Transocean extends losses after Songa deal; price paid for rigs &quot;staggering&quot;\" data-tweet=\"$RIG - Transocean extends losses after Songa deal; price paid for rigs &quot;staggering&quot; https://seekingalpha.com/news/3289951-transocean-extends-losses-after-songa-deal-price-paid-for-rigs-staggering?source=tweet\" data-url=\"https://seekingalpha.com/news/3289951-transocean-extends-losses-after-songa-deal-price-paid-for-rigs-staggering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289948\" data-ts=\"1502912187\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DCTH\" target=\"_blank\">DCTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289948-delcath-continues-up-move-shares-ahead-33\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Delcath continues up move, shares ahead 33%</a></h4><ul><li>Nano cap Delcath Systems (<a href='https://seekingalpha.com/symbol/DCTH' title='Delcath Systems, Inc.'>OTC:DCTH</a> <font color='green'>+33.1%</font>) is up on a whopping 122M shares, continuing its up move that began on August 3. Shares have almost doubled since then.</li><li>No particular news accounts for the action, but its Series B Preferred Stock (\"Recent Financial Transactions\" section of Q2 results <a href=\"https://www.sec.gov/Archives/edgar/data/872912/000119312517251408/d430684dex991.htm\" target=\"_blank\">press release</a>), issued to debt holders in July, is convertible into common shares at $0.153 so it's a good bet that that the rally will at least continue to trigger conversion.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289948\" data-linked=\"Delcath continues up move, shares ahead 33%\" data-tweet=\"$DCTH - Delcath continues up move, shares ahead 33% https://seekingalpha.com/news/3289948-delcath-continues-up-move-shares-ahead-33?source=tweet\" data-url=\"https://seekingalpha.com/news/3289948-delcath-continues-up-move-shares-ahead-33\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289945\" data-ts=\"1502910659\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289945-oil-turns-lower-despite-bullish-inventory-numbers-bond-yields-fall-well\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oil turns lower despite bullish inventory numbers; bond yields fall as well</a></h4><ul><li>The <a href=\"https://seekingalpha.com/news/3289856-crude-futures-pares-gains-post-inventory-data\" target=\"_blank\">EIA this morning</a> and API last night both reported far larger declines in stocks than had been expected. The data made for an early bump for black gold, but that's steadily reversed throughout the day, leaving WTI crude down 1.5% to $46.84 per barrel. <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>&nbsp;<font color='red'>-1.6%</font></li><li>In another interesting reversal, interest rates have moved lower since starting the day on the rise. The 10-year yield is now down five basis points to 2.228%. Released at 2 ET, <a href=\"https://seekingalpha.com/news/3289928-inflation-balance-sheet-wind-focus-fomc-minutes\" target=\"_blank\">minutes from the</a> FOMC's late-July meeting provided manna to both bulls and bears on fixed income. Some are worried about too-low inflation and wouldn't mind amping up the caution on more rate hikes; others (the ones in charge at the moment) are ready to hike again in September and begin paring the bloated balance sheet. <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='green'>+0.45%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='red'>-0.9%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3289945\" data-linked=\"Oil turns lower despite bullish inventory numbers; bond yields fall as well\" data-tweet=\"$USO $TLT $TBT - Oil turns lower despite bullish inventory numbers; bond yields fall as well https://seekingalpha.com/news/3289945-oil-turns-lower-despite-bullish-inventory-numbers-bond-yields-fall-well?source=tweet\" data-url=\"https://seekingalpha.com/news/3289945-oil-turns-lower-despite-bullish-inventory-numbers-bond-yields-fall-well\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>88&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289942\" data-ts=\"1502910478\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YY\" target=\"_blank\">YY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289942-yyminus-1_6-after-pricing-5_75m-share-offering-70\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">YY -1.6% after pricing 5.75M-share offering at $70</a></h4><ul>   <li>YY (<a href=\"http://seekingalpha.com/symbol/YY\" target=\"_blank\">YY</a> <font color='red'>-1.6%</font>) has <a href=\"https://seekingalpha.com/pr/16916843-yy-inc-announces-pricing-offering-american-depositary-shares\" target=\"_blank\">priced the 5.75M-share offering</a> in American depositary shares <a href=\"https://seekingalpha.com/news/3289290-yy-2_3-percent-new-463m-share-offering\" target=\"_blank\">that it announced Monday</a>.</li>    <li>The company's set the ADS price at $70 each. ADS had closed $80.58 Monday before the offering announcement; they fell 9.3% yesterday to $73.10 and are currently at $71.96.</li>    <li>That's $463M worth if an overallotment option for an additional 862,500 ADS is exercised.</li>    <li>Each ADS represents 20 class A common shares of the company.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289942\" data-linked=\"YY -1.6% after pricing 5.75M-share offering at $70\" data-tweet=\"$YY - YY -1.6% after pricing 5.75M-share offering at $70 https://seekingalpha.com/news/3289942-yyminus-1_6-after-pricing-5_75m-share-offering-70?source=tweet\" data-url=\"https://seekingalpha.com/news/3289942-yyminus-1_6-after-pricing-5_75m-share-offering-70\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289935\" data-ts=\"1502910351\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVO\" target=\"_blank\">NVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289935-novos-semaglutide-beats-lillys-dulaglutide-in-late-stage-study-in-type-2-diabetics-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novo&#39;s semaglutide beats Lilly&#39;s dulaglutide in late-stage study in type 2 diabetics; shares ahead 3%</a></h4><ul><li>Novo Nordisk (<a href='https://seekingalpha.com/symbol/NVO' title='Novo Nordisk A/S'>NVO</a> <font color='green'>+2.9%</font>) is up at Eli Lilly's (<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color='red'>-0.9%</font>) expense after it <a href=\"https://www.novonordisk.com/media/news-details.2127298.html\" target=\"_blank\">announced results</a> from the Phase 3b SUSTAIN 7 study comparing glucose control and weight loss in type 2 diabetics treated with either once-weekly semaglutide or Lilly's once-weekly <a href=\"https://www.trulicity.com/\" target=\"_blank\">Trulicity </a>(dulaglutide) over 40 weeks.</li><li>From a mean baseline HbA1c of 8.2%, patients receiving 0.5 mg of semaglutide achieved a statistically significant reduction of 1.5% compared to 1.1% for 0.75 mg of dulaglutide. Patients receiving 1.0 mg of semaglutide experienced a reduction of 1.8% versus 1.4% for 1.5 mg of dulaglutide.</li><li>The percentages of patients achieving their target HbA1c levels or below for the lower and higher doses of semaglutide and dulaglutide were 69%/52% and 79%/68%, respectively.</li><li>On the weight loss front, patients treated with 0.5 mg and 1.0 mg of semaglutide experienced mean weight loss of 4.6 kg and 6.5 kg, respectively. Patients receiving 0.75 mg and 1.5 mg of dulaglutide lost an average of 2.3 kg and 3.0 kg, respectively.</li><li>The percentages of patients who lost at least 5% of their body weight in the two doses of semaglutide were 44% and 63%, respectively, compared to 30% for 1.5 mg of dulaglutide.</li><li>Novo's marketing applications for semaglutide are currently under review in seven jurisdictions, including the U.S., EU and Japan.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3228597-novo-submits-u-s-marketing-application-long-acting-diabetes-med-semaglutide-t2d\" target=\"_blank\">Novo submits U.S. marketing application for long-acting diabetes med semaglutide in T2D</a> (Dec. 5, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289935\" data-linked=\"Novo&#39;s semaglutide beats Lilly&#39;s dulaglutide in late-stage study in type 2 diabetics; shares ahead 3%\" data-tweet=\"$NVO $NVO $LLY - Novo&#39;s semaglutide beats Lilly&#39;s dulaglutide in late-stage study in type 2 diabetics; shares ahead 3% https://seekingalpha.com/news/3289935-novos-semaglutide-beats-lillys-dulaglutide-in-late-stage-study-in-type-2-diabetics-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3289935-novos-semaglutide-beats-lillys-dulaglutide-in-late-stage-study-in-type-2-diabetics-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289939\" data-ts=\"1502909911\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WWE\" target=\"_blank\">WWE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289939-wwe-sets-new-australian-broadcast-deal-nine-network\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WWE sets new Australian broadcast deal with Nine Network</a></h4><ul>   <li>World Wrestling Entertainment (<a href=\"http://seekingalpha.com/symbol/WWE\" target=\"_blank\">WWE</a> <font color='green'>+1.6%</font>) has set up another Australian deal, an <a href=\"https://seekingalpha.com/pr/16916858-wwe-reaches-broadcast-agreement-nine-network\" target=\"_blank\">agreement with Nine Network</a> to broadcast its weekly flagship programs.</li>    <li>One-hour versions of <i>Raw</i> and <i>SmackDown</i> will air on the Australian network respectively on Thursdays at 11 p.m. and on Fridays after the conclusion of the 9Go Friday Night Movie.</li>    <li>Two weeks ago, the company had <a href=\"https://seekingalpha.com/news/3284156-wwe-extends-broadcast-deal-australias-foxtel\" target=\"_blank\">extended its similar deal</a> with Australia's Foxtel. The new deal expands its reach on the continent.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289939\" data-linked=\"WWE sets new Australian broadcast deal with Nine Network\" data-tweet=\"$WWE - WWE sets new Australian broadcast deal with Nine Network https://seekingalpha.com/news/3289939-wwe-sets-new-australian-broadcast-deal-nine-network?source=tweet\" data-url=\"https://seekingalpha.com/news/3289939-wwe-sets-new-australian-broadcast-deal-nine-network\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289938\" data-ts=\"1502909826\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289938-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FENG' title='Phoenix New Media Limited'>FENG</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/JRJC' title='China Finance Online Co. Limited'>JRJC</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/AKTS' title='Akoustis Technologies, Inc.'>AKTS</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/PNTR' title='Pointer Telocation Ltd.'>PNTR</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/DTRM' title='Determine, Inc.'>OTC:DTRM</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/CRDS' title='Crossroads Systems, Inc.'>CRDS</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/XGTI' title='xG Technology, Inc.'>XGTI</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289938\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$FENG $JRJC $AKTS - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3289938-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3289938-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289930\" data-ts=\"1502907915\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNMA\" target=\"_blank\">FNMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289930-frannie-gets-boost-from-ackman-comments\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Frannie gets boost from Ackman comments</a></h4><ul><li>Intrinsic value at Fannie Mae (<a href='https://seekingalpha.com/symbol/FNMA' title='Fannie Mae'>OTCQB:FNMA</a> <font color='green'>+2.9%</font>) and Freddie Mac (<a href='https://seekingalpha.com/symbol/FMCC' title='Freddie Mac'>OTCQB:FMCC</a> <font color='green'>+3.8%</font>) has increased significantly, says Bill Ackman on a Pershing Square conference call. He notes \"royalty-like\" cash flows from their single-family mortgage guarantee business.</li><li>He started investing in the GSEs four years ago, but the conventional wisdom then - that they would be wound down - no longer holds given Treasury Secretary Steven Mnuchin's views, says Ackman.</li><li>Source: Felice Maranz and Scott Deveau at Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3289930\" data-linked=\"Frannie gets boost from Ackman comments\" data-tweet=\"$FNMA $FNMA $FMCC - Frannie gets boost from Ackman comments https://seekingalpha.com/news/3289930-frannie-gets-boost-from-ackman-comments?source=tweet\" data-url=\"https://seekingalpha.com/news/3289930-frannie-gets-boost-from-ackman-comments\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>86&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289926\" data-ts=\"1502906496\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289926-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HBM' title='Hudbay Minerals Inc Ordinary Sh'>HBM</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/NAK' title='Northern Dynasty Minerals Ltd'>NAK</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/ZEUS' title='Olympic Steel, Inc.'>ZEUS</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/JONE' title='Jones Energy, Inc.'>OTC:JONE</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/TGB' title='Taseko Mines Limited'>TGB</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> EXXI <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/IPI' title='Intrepid Potash, Inc.'>IPI</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/MBII' title='Marrone Bio Innovations, Inc.'>MBII</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289926\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$HBM $NAK $ZEUS - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3289926-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3289926-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289919\" data-ts=\"1502903210\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289919-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings'>JP</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> RAS <font color='red'>-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289919\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$PN $JP $RASF - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3289919-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3289919-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289911\" data-ts=\"1502901992\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289911-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/JRJC' title='China Finance Online Co. Limited'>JRJC</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/FENG' title='Phoenix New Media Limited'>FENG</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/EROS' title='Eros International Plc'>EROS</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/CDTI' title='Clean Diesel Technologies, Inc.'>OTC:CDTI</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/KONA' title='Kona Grill, Inc.'>KONA</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/EVOK' title='Evoke Pharma, Inc.'>EVOK</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/NTEC' title='Intec Pharma'>NTEC</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/PNTR' title='Pointer Telocation Ltd.'>PNTR</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/RMGN' title='RMG Networks'>RMGN</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/RAVE' title='RAVE Restaurant Group, Inc.'>RAVE</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/IPCI' title='IntelliPharmaCeutics International Inc'>IPCI</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/WLDN' title='Willdan Group, Inc.'>WLDN</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='red'>-10%</font>. RAS <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/FLXS' title='Flexsteel Industries, Inc.'>FLXS</a> <font color='red'>-9%</font>. EXXI <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289911\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$JRJC $FENG $IDXG - Midday Gainers / Losers https://seekingalpha.com/news/3289911-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3289911-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289904\" data-ts=\"1502901053\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289904-snapplus-3_5-cantor-gets-bullish-suntrust-starts-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap +3.5%; Cantor gets bullish, SunTrust starts at Sell</a></h4><ul>     <li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) is <font color='green'>up 3.5%</font>, building momentum for the third day in a row following Monday's lockup expiration.</li>     <li>Cantor Fitzgerald upgraded shares to Overweight from Neutral, and hold a $17 price target (29% upside implied).</li>     <li>Meanwhile, SunTrust has joined the (relatively numerous) bears, <a href=\"www.cnbc.com/2017/08/16/suntrust-predicts-snap-will-plunge-more-than-20-percent-on-facebook-competition.html\" target=\"_blank\">initiating coverage of Snap at Sell</a> in a new report on social networking competitors.</li>     <li>Facebook's (<a href=\"http://seekingalpha.com/symbol/FB\" target=\"_blank\">FB</a> <font color='red'>-0.2%</font>) adoption of Snap's features is leading to faster growth, notes analyst Youssef Squali, and Facebook/Instagram and YouTube are \"quick followers, constantly improving their value proposition as well, at materially greater scale.\"</li>     <li>It's going to take time for Snap to overcome \"challenges around bringing advertisers onto the platform at scale, and getting a sizable portion of their ad spend short term.\"</li>     <li>He's set a price target for Snap of $10, implying 24% downside from today's pricing.</li>     <li>Meanwhile SunTrust has initiated Facebook at Buy, with a price target of $210 (23% upside implied) and Twitter (<a href=\"http://seekingalpha.com/symbol/TWTR\" target=\"_blank\">TWTR</a> <font color='green'>+1.3%</font>) at Hold, with a price target of $16 (vs. today's price of $16.15).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289904\" data-linked=\"Snap +3.5%; Cantor gets bullish, SunTrust starts at Sell\" data-tweet=\"$SNAP $SNAP $FB - Snap +3.5%; Cantor gets bullish, SunTrust starts at Sell https://seekingalpha.com/news/3289904-snapplus-3_5-cantor-gets-bullish-suntrust-starts-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3289904-snapplus-3_5-cantor-gets-bullish-suntrust-starts-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289900\" data-ts=\"1502900221\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBIO\" target=\"_blank\">PBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289900-pressure-biosciences-reports-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pressure BioSciences reports Q2 results</a></h4><ul><li>Pressure BioSciences (<a href='https://seekingalpha.com/symbol/PBIO' title='Pressure BioSciences, Inc.'>OTC:PBIO</a>): Q2 EPS of -$0.54</li><li>Revenue of $0.54M (+14.9% Y/Y)</li><li>Shares <font color='green'>+11%</font>.</li><li><a href='https://seekingalpha.com/pr/16917499-pressure-biosciences-inc-reports-second-quarter-2017-financial-results-provides-business'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3289900\" data-linked=\"Pressure BioSciences reports Q2 results\" data-tweet=\"$PBIO - Pressure BioSciences reports Q2 results https://seekingalpha.com/news/3289900-pressure-biosciences-reports-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3289900-pressure-biosciences-reports-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289898\" data-ts=\"1502899393\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289898-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> LTEA <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/OTIV' title='On Track Innovations Ltd'>OTIV</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/HOME' title='At Home Group'>HOME</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/FBR' title='Fibria Celulose S.A.'>FBR</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/FLXS' title='Flexsteel Industries, Inc.'>FLXS</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/DORM' title='Dorman Products, Inc.'>DORM</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/FFHL' title='Fuwei Films &#40;Holdings&#41; Co., Ltd.'>FFHL</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289898\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$LBCC $OTIV $HOME - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3289898-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3289898-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289889\" data-ts=\"1502898276\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NEFF\" target=\"_blank\">NEFF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289889-h-and-e-equipment-says-will-not-top-rival-bid-for-neff\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">H&amp;E Equipment says it will not top rival bid for Neff</a></h4><ul>     <li>Neff Corp. (<a href='https://seekingalpha.com/symbol/NEFF' title='Neff Corp.'>NEFF</a> <font color='red'>-6.1%</font>) plunges after H&amp;E Equpment (<a href='https://seekingalpha.com/symbol/HEES' title='H&E Equipment Services, Inc.'>HEES</a> <font color='green'>+1.5%</font>) says it <a href=\"https://seekingalpha.com/pr/16917381-neff-corporation-statement-transaction-update\" target=\"_blank\">will not submit a revised offer</a> to buy the company, following Monday's announced $25/share acquisition proposal from another bidder.</li>     <li>The news leaves Neff <a href=\"http://www.theadvocate.com/baton_rouge/news/business/article_a9e9553e-827c-11e7-a195-ef813e913c76.html\" target=\"_blank\">free to terminate</a> the previously announced merger agreement with H&amp;E, which requires Neff to pay $13.2M to H&amp;E if it backs out to accept another offer.</li>     <li>The deal with H&amp;E allowed Neff to seek other bids until Aug. 20; <a href=\"https://seekingalpha.com/news/3288918-neff-informs-h-and-e-better-buyout-offer\" target=\"_blank\">on Monday</a>, Neff said it had received an offer that was ~$90M higher than H&amp;E's.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289889\" data-linked=\"H&amp;E Equipment says it will not top rival bid for Neff\" data-tweet=\"$NEFF $NEFF $HEES - H&amp;E Equipment says it will not top rival bid for Neff https://seekingalpha.com/news/3289889-h-and-e-equipment-says-will-not-top-rival-bid-for-neff?source=tweet\" data-url=\"https://seekingalpha.com/news/3289889-h-and-e-equipment-says-will-not-top-rival-bid-for-neff\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289887\" data-ts=\"1502897935\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBRA\" target=\"_blank\">SBRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289887-sabra-and-care-capital-rise-after-merger-approved\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sabra and Care Capital both rise after merger approved</a></h4><ul><li>Overcoming opposition from shareholder advisory outfit ISS, owners of Sabra Health Care (<a href='https://seekingalpha.com/symbol/SBRA' title='Sabra Health Care REIT, Inc.'>SBRA</a> <font color='green'>+2.2%</font>) and Care Capital Properties (CCP <font color='green'>+3.4%</font>) each voted to approve the deal, which is scheduled to close on Aug. 17.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16916628-b-sabra-b-shareholders-approve-merger-care-capital-properties\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3289887\" data-linked=\"Sabra and Care Capital both rise after merger approved\" data-tweet=\"$SBRA - Sabra and Care Capital both rise after merger approved https://seekingalpha.com/news/3289887-sabra-and-care-capital-rise-after-merger-approved?source=tweet\" data-url=\"https://seekingalpha.com/news/3289887-sabra-and-care-capital-rise-after-merger-approved\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289885\" data-ts=\"1502897721\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HD\" target=\"_blank\">HD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289885-home-depot-bounces-back-solid-trends-highlighted\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Home Depot bounces back as solid trends highlighted</a></h4><ul> <li>Home Depot (NYSE:<a href='https://seekingalpha.com/symbol/HD' title='Home Depot, Inc.'>HD</a>) is <font color='green'>up 1.46%</font> after yesterday's somewhat puzzling downward move after a Q2 earnings topper.</li> <li>Analysts are doing their part to lift sentiment on the home improvement retailer.</li> <li>Raymond James (Outperform, $165 price target): \"Positive trends in housing turnover, housing starts, overall home affordability and the emergence of first-time homebuyers (typically owners of older homes) during the second quarter all point to an ongoing favorable domestic housing environment.\"</li><li>Wedbush: \"While some may pick at less-than-ideal incremental sales flow-through to profit in 2Q and guidance benefiting from higher share repurchases, we see the results and guidance as solid, particularly in comparison to the rest of retail.\"</li> <li><a href=\"http://www.chainstoreage.com/article/analyst-home-depots-q-performance-very-impressive\" target=\"_blank\">Chain Store Age</a> also has an interesting angle: \"Another tailwind is the difficulties of other retailers, especially in categories like appliances. Although this accounts for a much smaller slice of Home Depot's success, we nevertheless see the market share gains across these areas as a sign that Home Depot is advancing in segments that sit slightly outside of the traditional home improvement space. Notably, the number of women considering Home Depot for these categories has increased considerably over the past year.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3289377-comparable-sales-sparkle-home-depot\" target=\"_blank\">Comparable sales sparkle at Home Depot</a> (Aug. 15)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3289536-home-depot-lowes-bid\" target=\"_blank\">Home Depot and Lowe's bid down</a> (Aug. 15)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289885\" data-linked=\"Home Depot bounces back as solid trends highlighted\" data-tweet=\"$HD - Home Depot bounces back as solid trends highlighted https://seekingalpha.com/news/3289885-home-depot-bounces-back-solid-trends-highlighted?source=tweet\" data-url=\"https://seekingalpha.com/news/3289885-home-depot-bounces-back-solid-trends-highlighted\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289883\" data-ts=\"1502897328\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHP\" target=\"_blank\">BHP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289883-elliott-ups-stake-in-bhp-adopts-softer-tone\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Elliott ups stake in BHP but adopts softer tone</a></h4><ul>     <li>BHP Billiton (<a href='https://seekingalpha.com/symbol/BHP' title='BHP Billiton Limited'>BHP</a> <font color='green'>+1.5%</font>) is higher after Elliott Management said it <a href=\"https://seekingalpha.com/news/3289709-lot-activity-elliott-advisors\" target=\"_blank\">raised its stake</a> in the company to 5%, raising its stake from ~4.5% a month ago, as it continues to push for change.</li>     <li>But Elliott's tone <a href=\"https://www.wsj.com/articles/BT-CO-20170815-713711\" target=\"_blank\">appears to have softened</a> somewhat, as it says BHP has taken positive steps to improve its business and recent comments offered confidence that Chairman-elect Ken MacKenzie would heed shareholders' calls to take steps to enhance value for the company and its owners.</li>     <li>The steps include exiting the U.S. shale business \"and an in-depth, open and truly independent review of the petroleum business' place in BHP's portfolio.\"</li>     <li>Elliott's campaign <a href=\"http://www.reuters.com/article/us-bhp-billiton-elliott-idUSKCN1AV2JV?il=0\" target=\"_blank\">has achieved little so far</a>, says Andy Forster, senior investment officer at Argo Investments, adding of the shale business, \"They're not going to give it away.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3289883\" data-linked=\"Elliott ups stake in BHP but adopts softer tone\" data-tweet=\"$BHP - Elliott ups stake in BHP but adopts softer tone https://seekingalpha.com/news/3289883-elliott-ups-stake-in-bhp-adopts-softer-tone?source=tweet\" data-url=\"https://seekingalpha.com/news/3289883-elliott-ups-stake-in-bhp-adopts-softer-tone\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289880\" data-ts=\"1502896879\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMY\" target=\"_blank\">BMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289880-ubs-still-optimistic-bristol-myers-can-be-player-in-first-line-kidney-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UBS still optimistic that Bristol-Myers can be a player in first-line kidney cancer</a></h4><ul><li>UBS rates Bristol-Myers Squibb (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-1.1%</font>) a Buy with a $62 (8% upside) price target despite its recent setback with its Opdivo/Yervoy combo for the first-line treatment of renal cell carcinoma &#40;RCC&#41;, saying it still has a chance to participate in the indication considering the possibility of a positive effect on overall survival (data readout expected in Q3 2019).</li><li>The company plans to meet with the FDA to discuss the totality of the data. If the current results cannot support a marketing application, it will be a year behind Roche (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>) and Pfizer (NYSE:<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>), assuming they have positive data.</li><li>Preliminary results from Roche's Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02420821?titles=immotion+151&amp;spons=roche&amp;phase=2&amp;rank=1\" target=\"_blank\">IMmotion151</a> study evaluating the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) should be released early 2018.</li><li>Preliminary data from Pfizer's Phase 3 study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02684006?titles=javelin+renal+101&amp;spons=pfizer&amp;phase=2&amp;rank=1\" target=\"_blank\">JAVELIN Renal 101</a>, assessing the combination of Inlyta (axitinib) and Bavencio (avelumab), are expected in mid-2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3289664-late-stage-study-bristol-myers-opdivo-yervoy-combo-poor-risk-kidney-cancer-patients-shows\" target=\"_blank\">Late-stage study of Bristol-Myers' Opdivo/Yervoy combo in poor-risk kidney cancer patients shows mixed results; shares dip 2% after hours</a> (Aug. 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289880\" data-linked=\"UBS still optimistic that Bristol-Myers can be a player in first-line kidney cancer\" data-tweet=\"$BMY $BMY $RHHBY - UBS still optimistic that Bristol-Myers can be a player in first-line kidney cancer https://seekingalpha.com/news/3289880-ubs-still-optimistic-bristol-myers-can-be-player-in-first-line-kidney-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3289880-ubs-still-optimistic-bristol-myers-can-be-player-in-first-line-kidney-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289876\" data-ts=\"1502896402\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289876-healthcare-top-5-gainers-losers-of-11-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:10</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NTEC' title='Intec Pharma'>NTEC</a> <font color='green'>+15%</font>. COOL <font color='green'>+12%</font>.<a href='https://seekingalpha.com/symbol/IMMY-OLD' title='Imprimis Pharmaceuticals, Inc.'>IMMY-OLD</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/APEN' title='Apollo Endosurgery'>APEN</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/SENS' title='Senseonics Holdings'>SENS</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/KMDA' title='Kamada Ltd'>KMDA</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/IPCI' title='IntelliPharmaCeutics International Inc'>IPCI</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/CVM' title='Cel-Sci Corporation'>CVM</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/NVIV' title='InVivo Therapeutics Holdings Corp'>NVIV</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289876\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:10\" data-tweet=\"$NTEC $PTE $IMMY-OLD - Healthcare - Top 5 Gainers / Losers as of 11:10 https://seekingalpha.com/news/3289876-healthcare-top-5-gainers-losers-of-11-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3289876-healthcare-top-5-gainers-losers-of-11-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289870\" data-ts=\"1502895385\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFGC\" target=\"_blank\">PFGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289870-performance-food-group-reverses-early-post-earnings-dip\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Performance Food Group reverses early post-earnings dip</a></h4><ul> <li>Performance Food Group (NYSE:<a href='https://seekingalpha.com/symbol/PFGC' title='Performance Food Group'>PFGC</a>) is <font color='green'>up 1.64%</font> after an initial drop following its FQ4 earnings miss.</li> <li>Investors may be taking note of Performance Food's 2018 EPS growth forecast of 13% to 18%, in-line with consensus estimates.</li> <li>\"Our robust and consistent case growth, strong top-line growth, combined with increased gross profit per case, led to profitability at the high end of our expectations for fiscal 2017. Our strategic investments in fiscal 2017 will provide us with additional growth in fiscal 2018 and beyond,\" says CEO George Holm.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3289759-performance-food-group-misses-0_02-misses-revenue\" target=\"_blank\">Performance Food Group misses by $0.02, misses on revenue</a> (Aug. 16)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289870\" data-linked=\"Performance Food Group reverses early post-earnings dip\" data-tweet=\"$PFGC - Performance Food Group reverses early post-earnings dip https://seekingalpha.com/news/3289870-performance-food-group-reverses-early-post-earnings-dip?source=tweet\" data-url=\"https://seekingalpha.com/news/3289870-performance-food-group-reverses-early-post-earnings-dip\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289869\" data-ts=\"1502895122\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTNR\" target=\"_blank\">PTNR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289869-partner-communicationsplus-4_3-profits-rise-despite-revenue-drop\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Partner Communications +4.3% as profits rise despite revenue drop</a></h4><ul>   <li>Partner Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/PTNR' title='Partner Communications Company Ltd.'>PTNR</a>) is <font color='green'>up 4.3%</font> in Nasdaq trading after posting <a href=\"https://seekingalpha.com/news/3289754-partner-communication-reports-q2-results\" target=\"_blank\">Q2 earnings</a> where revenues slipped 10% but profits rose by nearly a third.</li>    <li>Revenues of 805M shekels fell 10% Y/Y and  missed expectations for 829M shekels (one estimate).</li>    <li>EBITDA came to 252M shekels ($72M), up 11%, and settled at 31% of total revenues vs. a previous 25%.</li>    <li>The company's cellular subscriber base withdrew by 1%, to about 2.66M. Cellular ARPU fell as well, down 5% to 62 shekels (about $18).</li>    <li>Revenue breakout: Service revenues, 646M shekels ($185M, down 7%); Equipment revenues, 159M ($45M, down 22%).</li>    <li>Adjusted free cash flow was 208M shekels (about $59M), up 48M from previous.</li>    <li><a href=\"https://www.partner.co.il/globalassets/global/PR_Q2_2017_isa.pdf\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3289869\" data-linked=\"Partner Communications +4.3% as profits rise despite revenue drop\" data-tweet=\"$PTNR - Partner Communications +4.3% as profits rise despite revenue drop https://seekingalpha.com/news/3289869-partner-communicationsplus-4_3-profits-rise-despite-revenue-drop?source=tweet\" data-url=\"https://seekingalpha.com/news/3289869-partner-communicationsplus-4_3-profits-rise-despite-revenue-drop\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289864\" data-ts=\"1502894530\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAOI\" target=\"_blank\">AAOI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289864-applied-optoelectronics-down-after-analyst-price-erosion-comments\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Applied Optoelectronics down after analyst price erosion comments</a></h4><ul><li>        Applied Optoelectronics (NASDAQ:<a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a>) trades down after BWS Financial analyst Hamed Khorsand reiterates his Sell rating and $25 price target following a conference call with the company.</li><li>               Khorsand said Applied&rsquo;s comments suggested accelerating price erosion that could drive down quarterly results and harm margins.</li><li>               Source: <a href=\"https://thefly.com/permalinks/entry.php/id2597358/AAOI-Applied-Optoelectronics-facing-price-erosion-says-BWS-Financial\" target=\"_blank\">The Fly</a>&nbsp;</li><li>               Applied Optoelectronics shares are&nbsp;<font color='red'>down 3.33%</font>. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3289864\" data-linked=\"Applied Optoelectronics down after analyst price erosion comments\" data-tweet=\"$AAOI - Applied Optoelectronics down after analyst price erosion comments https://seekingalpha.com/news/3289864-applied-optoelectronics-down-after-analyst-price-erosion-comments?source=tweet\" data-url=\"https://seekingalpha.com/news/3289864-applied-optoelectronics-down-after-analyst-price-erosion-comments\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>139&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289862\" data-ts=\"1502894286\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGEN\" target=\"_blank\">SGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289862-fda-accepts-seattle-genetics-marketing-application-for-adcetris-for-ctcl-action-date-december\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Seattle Genetics marketing application for Adcetris for CTCL, action date December 16; shares ahead 1%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16916923-fda-accepts-supplemental-biologics-license-application-grants-priority-review-adcetris\" target=\"_blank\">accepts for review</a> Seattle Genetics' (<a href='https://seekingalpha.com/symbol/SGEN' title='Seattle Genetics, Inc.'>SGEN</a> <font color='green'>+1.1%</font>) supplemental Biologics License Application (sBLA) seeking approval to use ADCETRIS (brentuximab vedotin) to treat patients with cutaneous T-cell lymphoma &#40;CTCL&#41;. The agency's action date is December 16, a Saturday, so expect an earlier decision.</li><li><a href=\"http://www.seattlegenetics.com/products/adcetris-us\" target=\"_blank\">ADCETRIS </a>is &nbsp;currently approved in the U.S. to treat certain patients with classical Hodgkin lymphoma and anaplastic large cell lymphoma.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289862\" data-linked=\"FDA accepts Seattle Genetics marketing application for Adcetris for CTCL, action date December 16; shares ahead 1%\" data-tweet=\"$SGEN - FDA accepts Seattle Genetics marketing application for Adcetris for CTCL, action date December 16; shares ahead 1% https://seekingalpha.com/news/3289862-fda-accepts-seattle-genetics-marketing-application-for-adcetris-for-ctcl-action-date-december?source=tweet\" data-url=\"https://seekingalpha.com/news/3289862-fda-accepts-seattle-genetics-marketing-application-for-adcetris-for-ctcl-action-date-december\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289856\" data-ts=\"1502893892\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289856-crude-futures-pares-gains-post-inventory-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude futures pares gains post inventory data</a></h4><ul>     <li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories</a>: Crude <strong>-8.9M</strong> barrels vs. -3.1M consensus, -6.5M last week.</li><li>Gasoline <b>Unchanged</b>&nbsp;vs. -1.1M consensus, +3.4M last week.</li><li>Distillates <strong>+0.7M</strong> vs. -0.60M consensus, -1.7M last week.</li><li>Futures&nbsp;<font color='green'>+0.4%</font>&nbsp;to $47.74.</li><li>ETFs:<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3289856\" data-linked=\"Crude futures pares gains post inventory data\" data-tweet=\"$USO $OIL $UCO - Crude futures pares gains post inventory data https://seekingalpha.com/news/3289856-crude-futures-pares-gains-post-inventory-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3289856-crude-futures-pares-gains-post-inventory-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>109&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289853\" data-ts=\"1502893136\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTEC\" target=\"_blank\">NTEC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289853-intec-prices-stock-offering-4_70-shares-up-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intec prices stock offering at $4.70; shares up 14%</a></h4><ul><li>Intec Pharma (<a href='https://seekingalpha.com/symbol/NTEC' title='Intec Pharma'>NTEC</a> <font color='green'>+13.9%</font>) <a href=\"https://seekingalpha.com/pr/16917232-intec-pharma-announces-pricing-50_0-million-public-offering-ordinary-shares\" target=\"_blank\">prices </a>its public offering of 10.6M ordinary shares at $4.70 per share yielding gross proceeds of almost $50M. Underwriters over-allotment is an additional 1.6M shares. Closing date is August 21.</li><li>Yesterday's close was $4.85.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3289622-intec-pharma-readies-equity-offering\" target=\"_blank\">Intec Pharma readies equity offering</a> (Aug. 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289853\" data-linked=\"Intec prices stock offering at $4.70; shares up 14%\" data-tweet=\"$NTEC - Intec prices stock offering at $4.70; shares up 14% https://seekingalpha.com/news/3289853-intec-prices-stock-offering-4_70-shares-up-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3289853-intec-prices-stock-offering-4_70-shares-up-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289851\" data-ts=\"1502893047\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDAY\" target=\"_blank\">WDAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289851-workday-acquires-customer-management-startup-founded-ex-googlers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Workday acquires customer management startup founded by ex-Googlers</a></h4><ul><li>        <a href=\"https://techcrunch.com/2017/08/16/workday-acquires-the-team-behind-pattern-a-young-startup-founded-by-ex-googlers/?ncid=rss&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+Techcrunch+%28TechCrunch%29\" target=\"_blank\">TechCrunch</a> reports that Workday (NYSE:<a href='https://seekingalpha.com/symbol/WDAY' title='Workday'>WDAY</a>) acquires Pattern, a customer relationship management startup founded by former Google employees.</li><li>               Terms of the deal not disclosed.&nbsp;</li><li>               The Pattern staff will join Workday.&nbsp;</li><li>               Workday shares are&nbsp;<font color='green'>up 1.71%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3277997-workday-plans-open-platform\" target=\"_blank\">Workday plans to open its platform</a> (July 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289851\" data-linked=\"Workday acquires customer management startup founded by ex-Googlers\" data-tweet=\"$WDAY - Workday acquires customer management startup founded by ex-Googlers https://seekingalpha.com/news/3289851-workday-acquires-customer-management-startup-founded-ex-googlers?source=tweet\" data-url=\"https://seekingalpha.com/news/3289851-workday-acquires-customer-management-startup-founded-ex-googlers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289849\" data-ts=\"1502892647\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMRA\" target=\"_blank\">BMRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289849-bioamerica-inks-distribution-deal-in-mexico-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bioamerica inks distribution deal in Mexico; shares ahead 2%</a></h4><ul><li>Thinly traded nano cap Biomerica (<a href='https://seekingalpha.com/symbol/BMRA' title='Biomerica, Inc.'>BMRA</a> <font color='green'>+2.4%</font>) perks up on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16917033-biomerica-announces-point-care-product-distribution-agreement-multinational-pharmaceutical\" target=\"_blank\">announcement </a>that it has inked an agreement with a multinational pharmaceutical firm for the distribution of one of its point-of-care products in Mexico. Specific details are not provided.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289849\" data-linked=\"Bioamerica inks distribution deal in Mexico; shares ahead 2%\" data-tweet=\"$BMRA - Bioamerica inks distribution deal in Mexico; shares ahead 2% https://seekingalpha.com/news/3289849-bioamerica-inks-distribution-deal-in-mexico-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3289849-bioamerica-inks-distribution-deal-in-mexico-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289848\" data-ts=\"1502892573\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBI\" target=\"_blank\">CBI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289848-cb-and-i-downgraded-jefferies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CB&amp;I downgraded at Jefferies</a></h4><ul><li>Chicago Bridge (NYSE:<a href='https://seekingalpha.com/symbol/CBI' title='Chicago Bridge & Iron Company'>CBI</a>) is <font color='red'>down 5.4%</font> in early trade after Jefferies <a href=\"https://www.streetinsider.com/Analyst+Comments/Jefferies+Downgrades+Chicago+Bridge+%26+Iron+%28CBI%29+to+Hold/13210778.html\" target=\"_blank\">lowered</a> its rating on the stock to Hold from Buy, with a price target of $12 (from $35).</li><li>The firm is concerned that cost overruns at the company's two LNG projects could re-emerge, adding risk to 2017-2019 earnings.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289848\" data-linked=\"CB&amp;I downgraded at Jefferies\" data-tweet=\"$CBI - CB&amp;I downgraded at Jefferies https://seekingalpha.com/news/3289848-cb-and-i-downgraded-jefferies?source=tweet\" data-url=\"https://seekingalpha.com/news/3289848-cb-and-i-downgraded-jefferies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>61&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289843\" data-ts=\"1502891772\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIAV\" target=\"_blank\">VIAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289843-notable-calls-viavi-losing-foothold-iphone-supplier\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Notable Calls: Viavi losing foothold as iPhone supplier</a></h4><ul><li>        <a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">Notable Calls</a> cites research from B. Riley &amp; Co. and William Blair showing that Viavi Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/VIAV' title='Viavi Solutions Inc.'>VIAV</a>) has lost its foothold as an iPhone supplier.</li><li>               B. Riley says future iPhones will only have one VIAV filter instead of two with an average selling price below $0.50.&nbsp;</li><li>               Viavi&rsquo;s remaining filter will be used for facial recognition apps through the front-facing camera but the rear-facing camera will use a standard IR filter, according to William Blair. &nbsp;&nbsp;&nbsp;</li><li>               Lumentum&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a>) VCSEL diode laser will likely appear in both cameras. &nbsp;&nbsp;</li><li>               Viavi shares are&nbsp;<font color='red'>down 6.16%</font>.&nbsp;</li><li>               Lumentum shares are&nbsp;<font color='red'>down 0.48%</font>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3289661-viavi-solutions-beats-q4-estimates-misses-guidance-shares-3_6-percent\" target=\"_blank\">Viavi Solutions beats Q4 estimates, misses on guidance; shares down 3.6%</a> (Aug. 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289843\" data-linked=\"Notable Calls: Viavi losing foothold as iPhone supplier\" data-tweet=\"$VIAV $VIAV $LITE - Notable Calls: Viavi losing foothold as iPhone supplier https://seekingalpha.com/news/3289843-notable-calls-viavi-losing-foothold-iphone-supplier?source=tweet\" data-url=\"https://seekingalpha.com/news/3289843-notable-calls-viavi-losing-foothold-iphone-supplier\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289840\" data-ts=\"1502891753\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MATN\" target=\"_blank\">MATN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289840-mateons-ca4p-fails-to-match-response-rate-of-placebo-regimen-in-treatment-resistant-ovarian\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mateon&#39;s CA4P fails to match response rate of placebo regimen in treatment-resistant ovarian cancer patients in Phase 2/3 study; shares down 3%</a></h4><ul><li>Interim data from a Phase 2/3 clinical trial assessing Mateon Therapeutics' (<a href='https://seekingalpha.com/symbol/MATN' title='Mateon Therapeutics, Inc.'>OTCQB:MATN</a> <font color='red'>-2.7%</font>) CA4P, combined with Roche's Avastin (bevacizumab) and physician's choice of chemo, in patients with platinum-resistant ovarian cancer showed only a modest treatment benefit.</li><li>Patients in the CA4P group experienced a median increase in progression-free survival &#40;PFS&#41; of 1.68 months compared to the control regimen (placebo + Avastin + chemo) The difference was not statistically significant, however.</li><li>Six patients (31.6%) in the CA4P arm and ten (47.6%) in the control arm progressed or died while on study, not unexpected since these patients have poor prognoses.</li><li>Partial responses were observed in 25.0% (n=4/16) of the subjects in the CA4P group compared to 31.6% (n=6/19) for the control regimen. The rates of stable disease were similar (56.3% vs. 57.9%).</li><li>The company says CA4P has a favorable safety profile, although most patients (57.9%) experienced transient increases in blood pressure (control: 9.5%) which generally peaked two hours following treatment and normalized ~two to three hours later. There was one case of grade 4 (life threatening)&nbsp;hypertensive crisis in the CA4P arm.</li><li><a href=\"http://www.oxigene.com/product-development/fosbretabulin\" target=\"_blank\">CA4P&nbsp;</a>is a vascular disrupting agent. It fights tumors by compromising the blood vessels that feed them, causing widespread ischemia (insufficient blood flow) and necrosis (tissue death) of the cancer cells within the core of the tumor.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289840\" data-linked=\"Mateon&#39;s CA4P fails to match response rate of placebo regimen in treatment-resistant ovarian cancer patients in Phase 2/3 study; shares down 3%\" data-tweet=\"$MATN - Mateon&#39;s CA4P fails to match response rate of placebo regimen in treatment-resistant ovarian cancer patients in Phase 2/3 study; shares down 3% https://seekingalpha.com/news/3289840-mateons-ca4p-fails-to-match-response-rate-of-placebo-regimen-in-treatment-resistant-ovarian?source=tweet\" data-url=\"https://seekingalpha.com/news/3289840-mateons-ca4p-fails-to-match-response-rate-of-placebo-regimen-in-treatment-resistant-ovarian\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289841\" data-ts=\"1502891512\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANGI\" target=\"_blank\">ANGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289841-angies-listplus-2_2-piper-jaffray-starts-overweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Angie&#39;s List +2.2% as Piper Jaffray starts at Overweight</a></h4><ul>   <li>Angie's List (NASDAQ:<a href='https://seekingalpha.com/symbol/ANGI' title='ANGI Homeservices Inc.'>ANGI</a>) is <font color='green'>up 2.2%</font> after Piper Jaffray opened bullish coverage seeing near 22% upside.</li>    <li>The firm launched with an Overweight rating and set a $14 price target.</li>    <li>That's higher than the typical $10.25 target, 21.7% higher than yesterday's close and 19% higher than today's price.</li>    <li>The company posted a miss in Q2 as it <a href=\"https://seekingalpha.com/news/3281480-angies-list-minus-2_7-percent-q2-swings-loss\" target=\"_blank\">swung to a loss</a> on declining revenues, but it still on track to be acquired in Q4 by IAC/HomeAdvisor.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289841\" data-linked=\"Angie&#39;s List +2.2% as Piper Jaffray starts at Overweight\" data-tweet=\"$ANGI - Angie&#39;s List +2.2% as Piper Jaffray starts at Overweight https://seekingalpha.com/news/3289841-angies-listplus-2_2-piper-jaffray-starts-overweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3289841-angies-listplus-2_2-piper-jaffray-starts-overweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289836\" data-ts=\"1502890856\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRC\" target=\"_blank\">SRC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289836-spirit-realty-up-2-after-two-notch-upgrade-baml\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spirit Realty up 2% after two-notch upgrade at BAML</a></h4><ul><li>The struggling triple-net lease player (<font color='red'>down 35%</font>&nbsp;Y/Y) is upgraded to Buy from Underperform at BAML, the team there seeing Q3 AFFO easily topping guidance.</li><li>The price target is lifted to $9.75 from $6.50. <a href='https://seekingalpha.com/symbol/SRC' title='Spirit Realty Capital'>SRC</a>&nbsp;<font color='green'>+2%</font>&nbsp;to $8.63.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289836\" data-linked=\"Spirit Realty up 2% after two-notch upgrade at BAML\" data-tweet=\"$SRC - Spirit Realty up 2% after two-notch upgrade at BAML https://seekingalpha.com/news/3289836-spirit-realty-up-2-after-two-notch-upgrade-baml?source=tweet\" data-url=\"https://seekingalpha.com/news/3289836-spirit-realty-up-2-after-two-notch-upgrade-baml\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:40 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289834\" data-ts=\"1502890688\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHU\" target=\"_blank\">CHU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289834-china-unicom-to-raise-11_7b-in-mixed-ownership-push\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Unicom to raise $11.7B in mixed-ownership push</a></h4><ul>   <li>China's push to inject private capital into its state-owned firms rolls on with China Unicom (<a href='https://seekingalpha.com/symbol/CHU' title='China Unicom &#40;Hong Kong&#41; Limited'>CHU</a> <font color='green'>+6.9%</font>) initiating Asia's <a href=\"https://www.reuters.com/article/us-china-unicom-results-idUSKCN1AW0JP?feedType=nl&amp;feedName=innovationNews&amp;utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=US%20Deals%20Today%202017-08-16&amp;utm_term=US%20Deals%20Today\" target=\"_blank\">biggest capital raise since 2010</a>.</li>    <li>China Unicom ADRs are at a two-year high on NYSE trading.</li>    <li>The telecom will raise about $11.7B from an investor group that includes Alibaba (<a href=\"http://seekingalpha.com/symbol/BABA\" target=\"_blank\">BABA</a> <font color='green'>+1.4%</font>), Tencent (<a href='https://seekingalpha.com/symbol/TCEHY' title='Tencent Holding Ltd. ADR'>OTCPK:TCEHY</a> <font color='green'>up 5%</font> premarket), Didi Chuxing, Baidu (<a href=\"http://seekingalpha.com/symbol/BIDU\" target=\"_blank\">BIDU</a> <font color='green'>+1.4%</font>) and JD.com (<a href=\"http://seekingalpha.com/symbol/JD\" target=\"_blank\">JD</a> <font color='green'>+1%</font>).</li>    <li>They'll get three board seats and a combined 35.2% stake in Unicom's Shanghai unit, China United Network Communications, whose board has approved issuing shares.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289834\" data-linked=\"China Unicom to raise $11.7B in mixed-ownership push\" data-tweet=\"$CHU $CHU $TCEHY - China Unicom to raise $11.7B in mixed-ownership push https://seekingalpha.com/news/3289834-china-unicom-to-raise-11_7b-in-mixed-ownership-push?source=tweet\" data-url=\"https://seekingalpha.com/news/3289834-china-unicom-to-raise-11_7b-in-mixed-ownership-push\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289831\" data-ts=\"1502890016\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FGEN\" target=\"_blank\">FGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289831-fibrogen-prices-stock-offering-40_75\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FibroGen prices stock offering at $40.75</a></h4><ul><li>FibroGen (NASDAQ:<a href='https://seekingalpha.com/symbol/FGEN' title='FibroGen'>FGEN</a>) <a href=\"https://seekingalpha.com/pr/16916763-fibrogen-inc-announces-pricing-follow-offering-common-stock\" target=\"_blank\">prices </a>its follow-on public offering of 8M shares of common stock at $40.75 per share. Underwriters over-allotment is an additional 1.2M shares. Closing date is August 21.</li><li>Yesterday's close was $41.30.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289831\" data-linked=\"FibroGen prices stock offering at $40.75\" data-tweet=\"$FGEN - FibroGen prices stock offering at $40.75 https://seekingalpha.com/news/3289831-fibrogen-prices-stock-offering-40_75?source=tweet\" data-url=\"https://seekingalpha.com/news/3289831-fibrogen-prices-stock-offering-40_75\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289828\" data-ts=\"1502889503\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289828-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/VIAV' title='Viavi Solutions Inc.'>VIAV</a>&nbsp;<font color='green'>-6%</font>&nbsp;on Q4 <a href=\"https://seekingalpha.com/news/3289620-viavi-solutions-beats-0_04-beats-revenue\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a> <font color='green'>-5%</font>&nbsp;on Q2 <a href=\"https://seekingalpha.com/news/3289770-xunlei-reports-q2-results\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/NEFF' title='Neff Corp.'>NEFF</a> <font color='green'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289828\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$VIAV $XNET $NEFF - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3289828-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3289828-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289827\" data-ts=\"1502889471\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TROV\" target=\"_blank\">TROV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289827-trovagenes-leukemia-candidate-pcmminus-075-shows-encouraging-action-in-preclinical-testing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trovagene&#39;s leukemia candidate PCM-075 shows encouraging action in preclinical testing with FLT3 inhibitor; shares ahead 12% premarket</a></h4><ul><li>Nano cap Trovagene (NASDAQ:<a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a>) is up&nbsp;<font color='green'>12%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16916916-trovagenes-plk1-inhibitor-pcmminus-075-preclinical-aml-data-significantly-enhances-efficacy\" target=\"_blank\">announcement </a>of positive results from preclinical testing in a xenograft model of the combination of PCM-075 and FLT3 inhibitor quizartinib. The company says the combo produced 96% tumor growth inhibition compared to 81% for quizartinib alone and 76% for PCM-075 alone.</li><li>The research data will be submitted for publication.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289827\" data-linked=\"Trovagene&#39;s leukemia candidate PCM-075 shows encouraging action in preclinical testing with FLT3 inhibitor; shares ahead 12% premarket\" data-tweet=\"$TROV - Trovagene&#39;s leukemia candidate PCM-075 shows encouraging action in preclinical testing with FLT3 inhibitor; shares ahead 12% premarket https://seekingalpha.com/news/3289827-trovagenes-leukemia-candidate-pcmminus-075-shows-encouraging-action-in-preclinical-testing?source=tweet\" data-url=\"https://seekingalpha.com/news/3289827-trovagenes-leukemia-candidate-pcmminus-075-shows-encouraging-action-in-preclinical-testing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289825\" data-ts=\"1502889222\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URBN\" target=\"_blank\">URBN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289825-urban-outfitters-and-peers-look-for-breakout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Urban Outfitters and peers look for breakout</a></h4><ul> <li>There's some buzzing in the apparel store sector after Urban Outfitters (NASDAQ:<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a>) topped some beaten-down estimates with its Q2 report. The company pointed to a stronger mix of regular-priced sales and indicated that the early part of Q3 is trending strong.</li> <li>Express (NYSE:<a href='https://seekingalpha.com/symbol/EXPR' title='Express, Inc.'>EXPR</a>) is <font color='green'>up 3.77%</font> premarket, Gap (NYSE:<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a>) is <font color='green'>1.04% higher</font> and American Eagle Outfitters (NYSE:<a href='https://seekingalpha.com/symbol/AEO' title='American Eagle Outfitters, Inc.'>AEO</a>) is tracking <font color='green'>1.28% higher</font>. Urban Outfitters (<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a>) is&nbsp;<font color='green'>up 22.35%</font>&nbsp;in premarket action and is bidding to open at +$20 for the first time since May.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3289628-urban-outfitters-flies-earnings-smasher\" target=\"_blank\">Urban Outfitters flies after earnings smasher</a> (Aug. 15)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3289825\" data-linked=\"Urban Outfitters and peers look for breakout\" data-tweet=\"$URBN $URBN $EXPR - Urban Outfitters and peers look for breakout https://seekingalpha.com/news/3289825-urban-outfitters-and-peers-look-for-breakout?source=tweet\" data-url=\"https://seekingalpha.com/news/3289825-urban-outfitters-and-peers-look-for-breakout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289824\" data-ts=\"1502889101\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289824-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a> <font color='green'>+21%</font>&nbsp;on Q2 <a href=\"https://seekingalpha.com/news/3289624-urban-outfitters-beats-0_07-beats-revenue\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/RADA' title='Rada Electronics Industries Limited'>RADA</a> <font color='green'>+15%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16916871-rada-receives-first-breakthrough-strategic-8-million-order-us-military\" target=\"_blank\">receiving</a> $8M order for U.S. military.</li><li><a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+14%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3289418-maxim-likes-interpace-diagnostics-sees-five-bagger\" target=\"_blank\">buy</a> rating from Maxim group.</li><li><a href='https://seekingalpha.com/symbol/PSTI' title='Pluristem Therapeutics, Inc.'>PSTI</a> <font color='green'>+11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3289780-u-s-dod-launch-pilot-study-pluristems-plx-r18-cell-therapy-radiation-exposure-shares-ahead-4\" target=\"_blank\">pilot study</a> of Pluristem's PLX-R18 cell therapy for radiation exposure.</li><li><a href='https://seekingalpha.com/symbol/A' title='Agilent Technologies Inc.'>A</a> <font color='green'>+5%</font>&nbsp;on Q3 <a href=\"https://seekingalpha.com/news/3289623-agilent-beats-0_07-beats-revenue\" target=\"_blank\">result</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289824\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$URBN $RADA $IDXG - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3289824-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3289824-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289812\" data-ts=\"1502888098\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIIB\" target=\"_blank\">BIIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289812-goldman-likes-biogen-sees-17-upside-shares-ahead-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman likes Biogen, sees 17% upside; shares ahead 1% premarket</a></h4><ul><li>Biogen (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>) is up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume. This morning, Goldman Sachs added it to its Conviction List with a $338 (17% upside) price target citing the promise of aducanumab in treating Alzheimer's disease. Analyst Terence Flynn adds that investor concerns with the multiple sclerosis franchise are \"overblown\" and the company's balance sheet is robust enough to support business development deals and share buybacks.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3289812\" data-linked=\"Goldman likes Biogen, sees 17% upside; shares ahead 1% premarket\" data-tweet=\"$BIIB - Goldman likes Biogen, sees 17% upside; shares ahead 1% premarket https://seekingalpha.com/news/3289812-goldman-likes-biogen-sees-17-upside-shares-ahead-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3289812-goldman-likes-biogen-sees-17-upside-shares-ahead-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289809\" data-ts=\"1502887502\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTEC\" target=\"_blank\">NTEC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289809-intec-pharma-down-5-premarket-on-planned-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intec Pharma down 5% premarket on planned equity offering</a></h4><ul><li>Thinly traded nano cap Intec Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/NTEC' title='Intec Pharma'>NTEC</a>) slips&nbsp;<font color='red'>5%</font>&nbsp;premarket on light volume in response to its upcoming <a href=\"https://seekingalpha.com/pr/16916519-intec-pharma-announces-proposed-public-offering-ordinary-shares\" target=\"_blank\">public offering</a> of ordinary shares.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3289622-intec-pharma-readies-equity-offering\" target=\"_blank\">Intec Pharma readies equity offering</a> (Aug. 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289809\" data-linked=\"Intec Pharma down 5% premarket on planned equity offering\" data-tweet=\"$NTEC - Intec Pharma down 5% premarket on planned equity offering https://seekingalpha.com/news/3289809-intec-pharma-down-5-premarket-on-planned-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3289809-intec-pharma-down-5-premarket-on-planned-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289807\" data-ts=\"1502887007\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GELYF\" target=\"_blank\">GELYF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289807-geely-passes-on-fiat-pursuit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Geely passes on Fiat pursuit</a></h4><ul> <li>Geely Automobile Holdings (<a href='https://seekingalpha.com/symbol/GELYF' title='Geely Automobile Holdings Ltd.'>OTCPK:GELYF</a>, <a href='https://seekingalpha.com/symbol/GELYY' title='Geely Automobile Holdings Ltd. ADR'>OTCPK:GELYY</a>) says it has <a href=\"http://www.autonews.com/article/20170816/OEM01/170819862/geely-says-it-has-no-plan-to-buy-fca\" target=\"_blank\">no plan</a> to acquire Fiat Chrysler Automobiles (NYSE:<a href='https://seekingalpha.com/symbol/FCAU' title='Fiat Chrysler Automobiles NV'>FCAU</a>).</li> <li>Automotive News reported last week that a large Chinese automaker was on the hunt for Fiat, leading to a guessing game over which company had the inside track.</li> <li>FCAU <font color='green'>+1.58%</font> premarket to $12.87. Investors may be reacting to Fiat's <a href=\"https://seekingalpha.com/news/3289715-fiat-joins-autonomous-driving-consortium\" target=\"_blank\">decision</a> to join a self-driving car consortium with Intel and BMW.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289807\" data-linked=\"Geely passes on Fiat pursuit\" data-tweet=\"$GELYF $GELYF $GELYY - Geely passes on Fiat pursuit https://seekingalpha.com/news/3289807-geely-passes-on-fiat-pursuit?source=tweet\" data-url=\"https://seekingalpha.com/news/3289807-geely-passes-on-fiat-pursuit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289806\" data-ts=\"1502886946\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTIC\" target=\"_blank\">CTIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289806-cti-biopharmas-pacritinib-may-potential-in-certain-myelofibrosis-patients-shares-ahead-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CTI BioPharma&#39;s pacritinib may have potential in certain myelofibrosis patients; shares ahead 4% premarket</a></h4><ul><li>Thinly traded micro cap CTI BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/CTIC' title='CTI BioPharma Corp.'>CTIC</a>) perks up&nbsp;<font color='green'>4%</font>&nbsp;premarket on light volume. The most recent news was a Seeking Alpha <a href=\"https://seekingalpha.com/article/4098642-cti-biopharmas-pacritinib-stand-today\" target=\"_blank\">article </a>published on Monday by Avisol Capital Partners pointing out that pacritinib may have potential in myelofibrosis &#40;MF&#41; patients who have platelet counts of 100K/uL or less, a subpopulation of MF patients where Incyte's <a href=\"http://www.jakafi.com/?utm_source=google&amp;utm_medium=cpc&amp;utm_campaign=G_ENG_Branded_Jakafi_DTC&amp;utm_content=G_Drug-Information_Jakafi_E&amp;utm_term=jakafi&amp;gclid=EAIaIQobChMImYrItOHb1QIVSRtpCh37wA-5EAAYASAAEgKCcfD_BwE&amp;gclsrc=aw.ds\" target=\"_blank\">Jakafi </a>(ruxolitinib) doesn't work well because the dose is limited to 5 mg instead of 20 mg.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289806\" data-linked=\"CTI BioPharma&#39;s pacritinib may have potential in certain myelofibrosis patients; shares ahead 4% premarket\" data-tweet=\"$CTIC - CTI BioPharma&#39;s pacritinib may have potential in certain myelofibrosis patients; shares ahead 4% premarket https://seekingalpha.com/news/3289806-cti-biopharmas-pacritinib-may-potential-in-certain-myelofibrosis-patients-shares-ahead-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3289806-cti-biopharmas-pacritinib-may-potential-in-certain-myelofibrosis-patients-shares-ahead-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289799\" data-ts=\"1502886094\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBRX\" target=\"_blank\">MBRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289799-moleculin-bio-acquires-new-brain-cancer-candidate-shares-ahead-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moleculin Bio acquires new brain cancer candidate; shares ahead 4% premarket</a></h4><ul><li>Nano cap Moleculin Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a>) perks up&nbsp;<font color='green'>4%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16916881-moleculin-acquires-active-drug-compound-treatment-brain-cancer\" target=\"_blank\">announcement </a>that it has secured exclusive access to a \"significant quantity\" of GMP-quality WP1122, a drug compound that it says has the potential to be a new approach to treating brain tumors, from its sublicense partner in Poland.</li><li>Research at MD Anderson in animal models showed that WP1122 has the potential to outperform current standard-of-care treatment for glioblastoma.</li><li>The company plans to accelerate preclinical toxicology and analytical testing of the compound in preparation for an IND filing in the U.S.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289799\" data-linked=\"Moleculin Bio acquires new brain cancer candidate; shares ahead 4% premarket\" data-tweet=\"$MBRX - Moleculin Bio acquires new brain cancer candidate; shares ahead 4% premarket https://seekingalpha.com/news/3289799-moleculin-bio-acquires-new-brain-cancer-candidate-shares-ahead-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3289799-moleculin-bio-acquires-new-brain-cancer-candidate-shares-ahead-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289795\" data-ts=\"1502885446\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ITRN\" target=\"_blank\">ITRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289795-on-ituran-locations-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Ituran Location&#39;s Q2</a></h4><ul>     <li>Ituran Location (NASDAQ:<a href='https://seekingalpha.com/symbol/ITRN' title='Ituran Location and Control Ltd.'>ITRN</a>) reports Location-based services revenue rose 18% to $41.7M in <a href=\"https://www.sec.gov/Archives/edgar/data/1337117/000117891317002458/exhibit_99-1.htm\" target=\"_blank\">Q2</a>, primarily due to increase in the subscriber base.</li>     <li>Wireless communications product revenue up 21.1% to $16.84M.</li>     <li>Net subscriber +30K in the quarter.</li>     <li>Subscriber base +9.9% Y/Y to 1,112K.</li>     <li>Gross margin rate down 10 bps to 51.6%.</li>     <li>Operating margin rate fell 10 bps to 24.2%.</li>     <li>EBITDA margin rate decreased 40 bps to 29.7%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289795\" data-linked=\"More on Ituran Location&#39;s Q2\" data-tweet=\"$ITRN - More on Ituran Location&#39;s Q2 https://seekingalpha.com/news/3289795-on-ituran-locations-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3289795-on-ituran-locations-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289792\" data-ts=\"1502885045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMY\" target=\"_blank\">BMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289792-bristol-myers-down-2-premarket-on-late-stage-results-from-kidney-cancer-study-rival-exelixis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bristol-Myers down 2% premarket on late-stage results from kidney cancer study; rival Exelixis up 3%</a></h4><ul><li>Bristol-Myers Squibb (NYSE:<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>) is down&nbsp;<font color='red'>2%</font>&nbsp;premarket on light volume on the heels of results from a Phase 3 clinical trial comparing Opdivo (nivolumab) + Yervoy (ipilimumab) against Pfizer's (NYSE:<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>) Sutent (sunitinib) in intermediate- and poor-risk kidney cancer patients. The study met one co-primary endpoint but missed another.</li><li>Exelixis (NASDAQ:<a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a>), marketer of kidney cancer med Cabometyx (cabozantinib), is up&nbsp;<font color='green'>3%</font>&nbsp;premarket on light volume. In June, an independent radiology review committee confirmed the results from a Phase 2 study that showed the superiority of Cabometyx over Sutent in the same population of kidney cancer patients.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3289664-late-stage-study-bristol-myers-opdivo-yervoy-combo-poor-risk-kidney-cancer-patients-shows\" target=\"_blank\">Late-stage study of Bristol-Myers' Opdivo/Yervoy combo in poor-risk kidney cancer patients shows mixed results; shares dip 2% after hours</a> (Aug. 15)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3274345-independent-review-affirms-positive-mid-stage-results-ipsen-exelixis-cabozantinib\" target=\"_blank\">Independent review affirms positive mid-stage results for Ipsen and Exelixis' cabozantinib</a> (June 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289792\" data-linked=\"Bristol-Myers down 2% premarket on late-stage results from kidney cancer study; rival Exelixis up 3%\" data-tweet=\"$BMY $BMY $PFE - Bristol-Myers down 2% premarket on late-stage results from kidney cancer study; rival Exelixis up 3% https://seekingalpha.com/news/3289792-bristol-myers-down-2-premarket-on-late-stage-results-from-kidney-cancer-study-rival-exelixis?source=tweet\" data-url=\"https://seekingalpha.com/news/3289792-bristol-myers-down-2-premarket-on-late-stage-results-from-kidney-cancer-study-rival-exelixis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289780\" data-ts=\"1502884029\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSTI\" target=\"_blank\">PSTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289780-u-s-dod-to-launch-pilot-study-of-pluristems-plx-r18-cell-therapy-for-radiation-exposure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. DoD to launch pilot study of Pluristem&#39;s PLX-R18 cell therapy for radiation exposure; shares ahead 4% premarket</a></h4><ul><li>The U.S. Department of Defense's Armed Forces Radiobiology Research Institute &#40;AFRRI&#41; will <a href=\"https://seekingalpha.com/pr/16916889-u-s-department-defense-conduct-studies-pluristem-s-plx-r18-new-ars-project-use-radiation\" target=\"_blank\">initiate </a>a pilot study evaluating Pluristem Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/PSTI' title='Pluristem Therapeutics, Inc.'>PSTI</a>) PLX-R18 cell therapy for the potential treatment of Acute Radiation Syndrome &#40;ARS&#41; prior to and within the first 24 hours of exposure to radiation.</li><li>The company recently <a href=\"http://www.pluristem.com/wp-content/uploads/2017/05/ARS-Pilot-Results_final.pdf\" target=\"_blank\">reported </a>positive results from a non-human primate study conducted by the National Institute of Allergy and Infectious Diseases &#40;NIAID&#41; that showed treatment with PLX-R18 improved survival rates and enhancement of blood lineages recovery.</li><li>Shares are up&nbsp;<font color='green'>4%</font>&nbsp;premarket on increased volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3262684-pluristem-plus-10-percent-promising-results-plx-r18\" target=\"_blank\">Pluristem +10% on promising results for PLX-R18</a> (May 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289780\" data-linked=\"U.S. DoD to launch pilot study of Pluristem&#39;s PLX-R18 cell therapy for radiation exposure; shares ahead 4% premarket\" data-tweet=\"$PSTI - U.S. DoD to launch pilot study of Pluristem&#39;s PLX-R18 cell therapy for radiation exposure; shares ahead 4% premarket https://seekingalpha.com/news/3289780-u-s-dod-to-launch-pilot-study-of-pluristems-plx-r18-cell-therapy-for-radiation-exposure?source=tweet\" data-url=\"https://seekingalpha.com/news/3289780-u-s-dod-to-launch-pilot-study-of-pluristems-plx-r18-cell-therapy-for-radiation-exposure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289770\" data-ts=\"1502883389\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XNET\" target=\"_blank\">XNET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289770-xunlei-reports-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xunlei reports Q2 results</a></h4><ul><li>Xunlei (NASDAQ:<a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>): Q2 EPS of -$0.02</li><li>Revenue of $41.5M (+8.9% Y/Y)</li><li>Shares <font color='green'>+1.73%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16916785-xunlei-announces-unaudited-financial-results-second-quarter-ended-june-30-2017'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3289770\" data-linked=\"Xunlei reports Q2 results\" data-tweet=\"$XNET - Xunlei reports Q2 results https://seekingalpha.com/news/3289770-xunlei-reports-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3289770-xunlei-reports-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289760\" data-ts=\"1502883218\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALBO\" target=\"_blank\">ALBO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289760-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Albireo Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ALBO' title='Albireo Pharma, Inc.'>ALBO</a>) initiated with Outperform rating by Cowen and Company.</li><li>ObsEva (NASDAQ:<a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva'>OBSV</a>) initiated with Outperform rating and $18 (134% upside) price target by Leerink.</li><li>Dextera Surgical (<a href='https://seekingalpha.com/symbol/DXTR' title='Dextera Surgical Inc.'>OTC:DXTR</a>) initiated with Buy rating and $0.80 (220% upside) price target by Ladenburg Thalmann.</li><li>Spectrum Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a>) resumed with Buy rating and $14 (49% upside) price target by H.C. Wainwright citing upside with Rolontis and poziotinib.</li><li>Biogen (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>) added to Conviction Buy List at Goldman Sachs.</li><li>Mylan N.V. (NASDAQ:<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a>) upgraded to Buy by Citigroup. Shares up&nbsp;<font color='green'>3%</font>&nbsp;premarket.</li><li>Prometic Life Sciences (<a href='https://seekingalpha.com/symbol/PFSCF' title='ProMetic Life Sciences Inc.'>OTCQX:PFSCF</a>) downgraded to Sector Perform by National Bank.</li><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) downgraded to Neutral by Citigroup.</li><li>Aevi Genomic Medicine (NASDAQ:<a href='https://seekingalpha.com/symbol/GNMX' title='Aevi Genomic Medicine, Inc.'>GNMX</a>) price target lowered to $7 (407% upside) from $9 by Needham citing dilution from recent financing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289760\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$ALBO $ALBO $OBSV - Premarket analyst action - healthcare https://seekingalpha.com/news/3289760-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3289760-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289769\" data-ts=\"1502883106\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGT\" target=\"_blank\">TGT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289769-target-rallies-after-lifting-profit-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Target rallies after lifting profit guidance</a></h4><ul> <li>Target (NYSE:<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a>) <a href=\"http://investors.target.com/phoenix.zhtml?c=65828&amp;p=irol-newsArticle&amp;ID=2294141\" target=\"_blank\">reports</a> comparable sales increased 1.3% in Q2 to top the consensus estimate for a 0.7% gain.</li> <li>Comparable digital channel sales rose 32% during the quarter to contribute 1.1 percentage points to comparable sales growth.</li> <li>The retailer's gross margin rate fell back 40 bps to 30.5% vs. 31.0% consensus as aggresssive pricing played in. Adjusted EBIT came in at 6.8% of sales vs. 7.7% a year ago.</li> <li>Looking ahead, Target expects Q3 EPS of $0.75 to $0.95 vs. $0.79 consensus and full-year EPS of $4.34 to $4.54 vs. $3.80 to $4.20 prior and $4.39 consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3289738-target-beats-0_04-beats-revenue\" target=\"_blank\">Target beats by $0.04, beats on revenue</a> (Aug. 16)</li> <li>TGT <font color='green'>+4.88%</font> premarket to $57.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289769\" data-linked=\"Target rallies after lifting profit guidance\" data-tweet=\"$TGT - Target rallies after lifting profit guidance https://seekingalpha.com/news/3289769-target-rallies-after-lifting-profit-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3289769-target-rallies-after-lifting-profit-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289738\" data-ts=\"1502879877\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGT\" target=\"_blank\">TGT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289738-target-beats-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Target beats by $0.04, beats on revenue</a></h4><ul><li>Target (NYSE:<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a>): Q2 EPS of $1.23 <font color='green'>beats by $0.04</font>.</li><li>Revenue of $16.43B (+1.6% Y/Y) <font color='green'>beats by $130M</font>.</li><li>Shares <font color='green'>+4.88%</font> PM.</li><li><a href='http://investors.target.com/phoenix.zhtml?c=65828&p=irol-newsArticle&ID=2294141'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3289738\" data-linked=\"Target beats by $0.04, beats on revenue\" data-tweet=\"$TGT - Target beats by $0.04, beats on revenue https://seekingalpha.com/news/3289738-target-beats-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3289738-target-beats-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":65,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}